Isordia-Salas, Irma <br/><br/>
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.  [electronic resource] 

 -  Thrombosis research  Sep 2012 
 - e67-72 p.  digital 
<br/><br/> Publication Type: Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1879-2472 
<br/><br/><label>Standard No.: </label>10.1016/j.thromres.2012.06.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--drug therapy<br/>Aspirin--therapeutic use<br/>Clopidogrel<br/>Comorbidity<br/>Cytochrome P-450 CYP3A--genetics<br/>Drug Resistance--genetics<br/>Female<br/>Genetic Predisposition to Disease--epidemiology<br/>Genetic Variation--genetics<br/>Humans<br/>Male<br/>Mexico--epidemiology<br/>Middle Aged<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Platelet Glycoprotein GPIIb-IIIa Complex--genetics<br/>Polymorphism, Single Nucleotide--genetics<br/>Prevalence<br/>Receptors, Purinergic P2Y12--genetics<br/>Risk Factors<br/>Thrombosis--epidemiology<br/>Ticlopidine--analogs & derivatives<br/>Treatment Outcome